Kanchan Mukherjee: Bedaquiline for multidrug-resistant TB in India — at what cost?

In a blog post in The BMJ Opinion, Kanchan Mukherjee, a medical doctor and professor at the Tata Institute of Social Sciences in Mumbai, discusses the potential benefits and challenges of a wider government rollout of bedaquiline to treat multidrug-resistant TB in India.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By Kanchan Mukherjee

Published: June 22, 2018, 9:12 p.m.

Last updated: June 22, 2018, 9:15 p.m.

Print Share